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13,396 males representing 212.7 million American adults aged
18 to 85+ years. Nonparametric regression models were
employed to express migraine prevalence as a function of age
separately for each sex group. The salient characteristics of the
ﬁtted functions were evaluated by examining the ﬁrst and second
derivatives, corresponding to the velocity and the acceleration of
prevalence over the age continuum. RESULTS: Study results
suggest that migraine prevalence increases with age until about
34 years, where it reaches a maximum, then starts declining until
75 years where it reaches a plateau for both sexes. For females,
the greatest rate of decline in migraine prevalence starts at 41
years and continues until age 63 where it reaches its minimum.
The rate of decline in migraine prevalence for males, on the other
hand, seems to be decreasing in a smooth monotonic fashion
starting age 34 and reaches the female rate of change at 78 years.
The dramatic change in both the slope and the curvature of the
function for females around the perimenopausal age range war-
rants attention. CONCLUSIONS: These ﬁndings provide indi-
rect evidence for the phenomenon of menstrual migraine. The
inﬂection points on the female curve correspond to the age range
of perimenopause and menopause in U.S. women. These inﬂec-
tion points are not observed on the male curve.
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OBJECTIVES: Phase III clinical trials showed novel drugs intro-
duced in the 1990s modiﬁed the natural history (NH) of relaps-
ing-remitting onset deﬁnite multiple sclerosis (MS). A Nova
Scotia Phase IV “real world” observational study conﬁrmed the
short-term effectiveness of these disease modifying therapies
(MS-DMT), measured by Extended Disability Status Scale
(EDSS) increase avoided per patient per year. This analysis pro-
jects these short-term results over a 20-year horizon to estimate
long-term health outcomes of MS-DMT. METHODS: A proba-
bilistic Markov model estimated EDSS progression for NH and
MS-DMT cohorts with relapsing-remitting onset MS over a 20-
year horizon. The model was based on 591 patients receiving
MS-DMT from the Dalhousie MS Research Unit, stratiﬁed into
three subgroups by ﬁnal classiﬁcation and disability severity: 1)
mild relapsing-remitting MS (RRMS), 2) mild secondary-pro-
gressive MS (SPMS) and 3) mild or moderate SPMS. Health out-
comes were measured as EDSS disability adjusted life years
(DALYs) avoided per patient compared to NH. Relative beneﬁt
was deﬁned as DALY burden avoided relative to expected
DALYs given NH. The baseline analysis was a “best-case” sce-
nario with full compliance for 20 years. RESULTS: The model
found statistically signiﬁcant beneﬁt in all three subgroups.
Among the mild severity subgroups, there were 1.7 (95%
CI:1.2–2.2) DALYs avoided among RRMS patients and 2.6
(1.5–3.6) DALYs avoided among SPMS patients, for a combined
beneﬁt of 1.9 (1.2–3.2) DALYs avoided, or a 42% (20%–91%)
relative beneﬁt. Among the mild or moderate SPMS patients
there were 1.1 (0.3–1.9) DALYs avoided (14%; 3–30%).
Overall, the combined cohort had a beneﬁt of 1.5 (0.5–2.1)
DALYs avoided (29%; 6–63%). CONCLUSIONS: MS-DMT
can have signiﬁcant long-term beneﬁt in terms of DALYs
avoided, particularly in mild subgroups. This analysis is the ﬁrst
to model long-term change in mean EDSS, rather than delayed
time to speciﬁc EDSS endpoints, and may help guide MS-DMT
coverage decisions.
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OBJECTIVES: To describe and compare the domains and psy-
chometric properties of selected Patient Reported Outcomes
(PROs) instruments, neuropsychological and cognitive, devel-
oped and/or used in patients with Parkinson’s disease (PD).
METHODS: A systematic literature review of published studies
was conducted using MEDLINE (1990–2006), EMBASE
(1990–2006) and the Mapi Research Trust databases. Only
studies describing the development or use of a referenced instru-
ment assessing Health-Related Quality Of Life (HRQL), Activi-
ties of Daily Living (ADL), Fatigue/sleep, Neuropsychological
and cognitive measures were included in the review. Instruments
were selected if they were speciﬁcally developed for Parkinson’s
disease, or used in clinical trials and for which psychometric
properties were available. Caregiver reports were not included.
RESULTS: Sixty instruments were identiﬁed and 35 were
selected for in-depth review. Seven questionnaires measured
HRQL (2 generic and 5 PD speciﬁc). Of these, the PDQUALIF
and the PDQ-39 are well validated but are not always sensitive
to changes in RCTs. Four instruments assessed ADL/disability,
with the UPDRS being generally used as a primary endpoint in
RCTs. Six instruments measured sleep or fatigue, most of them
have been validated in PD patients and are sensitive to change.
Two symptoms (motor & non-motor) scales were selected, but
lack evidence of good psychometric properties. Four psycholog-
ical instruments and 12 neuropsychological/cognitive instru-
ments were also selected. Most of these were not validated in PD
patients and failed to demonstrate their sensitivity to change in
clinical trials. CONCLUSIONS: The selected PRO instruments
are very heterogeneous in their levels of validation, psychomet-
ric properties and sensitivity to change in clinical trials, depend-
ing on the dimension measured. For HRQOL, ADL/Disability
and Sleep, reliable measures are available whereas advances 
are still needed to assess symptoms, psychological well-being or
cognition.
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OBJECTIVES: Treatment of epilepsy is still challenging to the
scientiﬁc community. Usually, these patients require more than
one drug. Hence satisfaction with antiepileptic drugs becomes a
major goal, as it is of crucial relevance for seizures control and
patient wellbeing, particularly at the level of anxiety, depression
and quality of life. This study assessed the psychometric prop-
erties of a recently developed questionnaire of Treatment Satis-
faction (SATMED-Q) in subjects with refractory epilepsy.
METHODS: patients with refractory epilepsy from epilepsy and
neurology outpatient clinics, representative of the national dis-
tribution in Spain were included. Sociodemographic, anthropo-
metric data, and the SATMED-Q (Treatment Satisfaction), and
HAD (Anxiety and Depression) questionnaires were collected.
Reliability and validity were determined. Factor analysis was
used to check the instrument original structure. RESULTS: A
sample of 768 consecutive patients [average age of 40.5 (13.5)
years, 50.8% males and 24.3 (13.4) years of disease evolution]
